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Mesenchymal stem cells and psoriasis: State of the art and
future perspectives
Dear Editor
Mesenchymal stem cells (MSCs) are a subset of pluripotent cells present
in tissues of mesenchymal origin and responsible for their regeneration.
MSCs include many different cell types, probably the most widely stud-
ied being the bone marrow stromal stem cells (BMSCs). Other types
of MSCs are, for example, umbilical cord mesenchymal stem cells
(UCMSCs), amniotic fluid stem cells (Amn-MSC), and adipose-derived
stem cells (ADSCs). MSCs are currently widely studied not only for their
regenerative capacity but also for their immunomodulating properties,
thus giving reason to their use in clinical trials for autoimmune and
autoinflammatory disorders. In this setting, several authors have investi-
gated the role of MSCs as a possible therapeutic strategy for the treat-
ment of psoriasis in both clinical and preclinical models.
Previous studies already confirmed the involvement of MSCs in the
pathogenesis of the disease and, therefore, designated MSCs as
important potential therapeutic targets in the setting of psoriasis (Niu &
Zhang, 2016). Liu and coworkers stated that lymphocyte inhibition is
compromised in psoriatic skin, mainly because of MSCs in psoriatic
lesions leading to abnormalities in cytokine secretion (Liu, Yang, Yan, &
Zhang, 2013). MSCs from skin lesions of psoriatic patients also promote
keratinocyte proliferation, resulting in abnormal thickening of the epi-
dermis (Figure 1). Moreover, several papers reported on the central role
played by MSCs in response to biologic therapies: MSCs in fact seem to
be key players in mediating the pleiotropic effects of those drugs on
both keratinocytes and T cells. Campanati and coauthors in particular
demonstrated that the effects of TNF-alpha inhibitors take place at the
level of dermal MSCs, which probably represent the cells primarily
involved in the “psoriatic march” (Campanati et al., 2017).
To date, only few anecdotal reports of patients treated with
MSC-based regimens have been published. A total of six patients
F IGURE 1 Schematic
representation of the role of
mesenchymal stem cell in psoriasis.
Under physiological conditions, skin-
resident T lymphocytes and
Langerhans cells are in a quiescent
state and epithelial renewal is finely
controlled. On the contrary, MSC
dysfunction results in secretion of
proinflammatory cytokines and local
recruitment of activated Th1 and
Th17 lymphocytes, responsible for
the hyperkeratosis, parakeratosis, and
papillomatosis typical of psoriatic
plaques. Although therapies of
conventional immunosuppressants
for psoriasis only act on lymphocyte
modulation, biologic therapies have a
combined action on both cytokine
and MSC modulation. The aim of
MSC-based therapeutic regimens is
to restore a physiological
nondysfunctional MSC population
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affected by psoriasis have been described in four clinical studies. Of
them, two patients received intravenous injection of UCMSCs and
three of ADSCs, while only one patient was treated with topical appli-
cation of ADSC-conditioned medium. So far, MSC-based therapies
proved their efficacy in all described cases (Chen et al., 2016).
However, most of the research is today still limited to the bench
side. Preclinical studies, mainly using imiquimod-induced murine
models of psoriasis, have in fact recently stressed the potential thera-
peutic efficacy of MSCs, with surprisingly promising results (Chen
et al., 2019). However, no standardized experimental models are cur-
rently available, since huge differences both in the type of MSC used
(dermal MSCs, ADSCs, UCMSCs, and embryonic stem cell-derived
MSCs) and the administration route (intravenous, intralesional, and
topical) can be found in the literature. The effects of MSC administra-
tion are certainly mediated by their well-known immunomodulating
action on both T cells and dendritic cells through cytokine secretion.
However, the possibility of a direct interaction between MSCs and
keratinocytes remains unknown and should be clarified. Another
important point for future research is the possibility of obtaining effi-
cient MSC from psoriatic patients: since dermal MSCs in psoriatic
plaques have been shown to be altered, also other MSCs could be
impaired in terms of function and it is therefore imperative to check
whether autologous MSCs can be efficiently used for psoriasis
treatment.
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